2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Gopa Iyer, MD, discusses the unmet needs for patients with solid tumors harboring TSC1/2 mutations.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Gopa Iyer, MD, section head, Bladder Cancer, Memorial Sloan Kettering Cancer Center, discusses the unmet needs for patients with solid tumors harboring TSC1/2 mutations.
Although standard-of-care treatments exist for patients with TSC1/2 mutations across different cancer types, these patients may ultimately experience disease progression over time, Iyer explains. Developing a targeted therapy for solid tumors harboring TSC1/2 mutations remains an intriguing avenue for research, Iyer adds.
TSC1/2 mutations are relatively rare among individual tumor types; however, the collective population across different solid tumors represents a meaningful number of patients. A tumor-agnostic targeted therapy would stand to benefit these patients, Iyer adds.
The safety and efficacy of nab-sirolimus (ABI-009) monotherapy is under evaluation in the phase 2 PRECISION 1 trial (NCT05103358), a basket study that is currently enrolling patients with malignant solid tumors harboring pathogenic inactivating TSC1 or TSC2 alterations.
Related Content: